Uganda’s Minister of Science, Technology, and Innovations, Dr. Musenero, defended her decision to purchase mice at Shs8 million each for COVID-19 vaccine research, asserting that they were the most economical option available.
Dr. Monica Musenero clarified that these mice were unique, containing human genes, and were highly sought after in the scientific community. Addressing a research dissemination workshop organized by Ahaki, she recounted the challenges faced in acquiring these specialized mice, highlighting the misconception among Ugandans regarding the requirements for scientific research.
She explained that despite initial difficulties in procurement, the four mice obtained have multiplied to 160, with the aim of conducting clinical trials in collaboration with the National Drug Authority (NDA) in the upcoming fiscal year.
Acknowledging the criticism she faced, particularly regarding the utilization of funds for vaccine development, Dr. Musenero emphasized the importance of transparent and equitable vaccine distribution agreements, citing the challenges faced by African countries in accessing COVID-19 vaccines.
Dr. Daniel Kyabayinze, Director of Public Health at the Ministry of Health, echoed concerns about the terms imposed by Western countries during vaccine procurement, underscoring the need for African nations to prioritize vaccine manufacturing to enhance self-sufficiency.
In line with Uganda’s efforts in vaccine research, Prof. Pontiano Kaleebu, Director of Uganda Virus Research Institute, highlighted ongoing projects, including the development of COVID-19 vaccines and research on other infectious diseases.
Despite the challenges faced, Uganda remains committed to advancing scientific research and vaccine development to address public health challenges both nationally and globally.
ALSO READ:
